Androgen deprivation therapy or ADT – a common therapy for prostate cancer that lowers levels of the male hormone testosterone – may also increase the risk of developing Alzheimer’s later on.
The study found that men who were on the testosterone-lowering therapy the longest were the ones most likely to be diagnosed with Alzheimer’s disease in the years that followed the start of the treatment.

 

CLICK HERE TO READ MORE